AB122 + AB154 vs. Pembrolizumab in 1st line PDL1- High NSCLC

A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

For More Information:

https://clinicaltrials.gov/study/NCT04736173?term=A%20Phase%203%20Study%20to%20Evaluate%20Zimberelimab%20(AB122)%20Combined%20with%20Domvanalimab%20(AB154)%20Compared%20to%20Pembrolizumab%20in%20Front-Line,%20PD-L1-High,%20Locally%20Advanced%20or%20Metastatic%20Non-Small%20Cell%20Lung%20Cancer&rank=1